BRAF and melanoma: The randomized, phase 3 COMBI-I trial evaluated the efficacy of spartalizumab, dabrafenib and trametinib compared to placebo, dabrafenib and trametinib as first line treatment of patients with unresectable BRAF mutant melanoma.